Condition: Advanced Solid Tumor · Sponsor: RemeGen Co., Ltd.
In Phase I, This study will explore the tolerability and safety of RC118 in patients with locally advanced unresectable or metastatic malignant solid tumors with positive Claudin 18.2 expression, and determine the maximum tolerated dose (MTD) and the recommended dose in phase II clinical trials (RP2D); In Phase IIa, to explore the clinical effectiveness and safety of long-term use of RC118 at RP2D doses for patients with different tumor types。
This description comes directly from the study's public registry record.
Jianming Fang, ph.D · +8610-58075763 · jianmingfang@hotmail.com
Always discuss trial participation with your own doctor first.
| Zhongshan Hospital Affiliated to Fudan University | Shanghai, Shanghai Municipality, China | Recruiting |
| The first affiliated hospital, zhejiang universtity school of medicine | Hangzhou, Zhejiang, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05205850